Evidence map›Paper›PMID 9920522›Full record

Trial reportAtherosclerosis1999

Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease.

M C Cheung, G Wolfbauer, B G Brown, J J Albers

Registry-linked trialAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Atherosclerosis, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000553. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000553 phase3completed

HDL-Atherosclerosis Treatment Study (HATS)

Ran1994Registered outcomes0Posted comparisons0ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial IschemiaArmsAntioxidants, niacin, simvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 35 citations in OpenAlex.

  1. Electronic Cigarette Use and the Risk of Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

M C CheungDepartment of Medicine, University of Washington, Seattle, USA.
G Wolfbauer
B G Brown
J J Albers
University of Washington · US

Funding

Serum Amyloid and Inflammation in AtherogenesisP01HL030086 · NHLBI · UNIVERSITY OF WASHINGTON · PI HEINECKE, JAY W · 1985 to 2009
$14.7M
DOES ATHEROSCLEROSIS REGRESS WITH THERAPY FOR LOW HDLC?R01HL049546 · NHLBI · UNIVERSITY OF WASHINGTON · PI BROWN, BRUCE G · 1994 to 2000
$326k
NHLBI NIH HHS HL30086NHLBI NIH HHS HL49546
6 · The paper itself

Abstract

Low levels of high density lipoproteins (HDL) are associated with an increased risk for premature cardiovascular disease. The plasma phospholipid transfer protein (PLTP) is believed to play a critical role in lipoprotein metabolism and reverse cholesterol transport by remodeling HDL and facilitating the transport of lipid to the liver. Plasma contains two major HDL subclasses, those containing both apolipoproteins (apo) A-I and A-II, Lp(A-I, A-II), and those containing apo A-I but not A-II, Lp(A-I). To examine the potential relationships between PLTP and lipoproteins, plasma PLTP activity, lipoprotein lipids, HDL subclasses and plasma apolipoproteins were measured in 52 patients with documented cardiovascular disease and low HDL levels. Among the patients, plasma PLTP activity was highly correlated with the percentage of plasma apo A-I in Lp(A-I) (r=0.514, p < 0.001) and with the apo A-I, phospholipid and cholesterol concentration of Lp(A-I) (r=0.499, 0.478, 0.457, respectively, p < 0.001). Plasma PLTP activity was also significantly correlated with plasma apo A-I (r=0.413, p=0.002), HDL cholesterol (r=0.308, p=0.026), and HDL, and HDL3 cholesterol (r=0.284 and 0.276, respectively, p < 0.05), but no significant correlation was observed with Lp(A-I, A-I), plasma cholesterol, triglycerides, or apo B, very low density lipoprotein cholesterol or low density lipoprotein cholesterol. These associations support the hypothesis that PLTP modulates plasma levels of Lp(A-I) particles without significantly affecting the levels of Lp(A-I, A-II) particles.

Indexed as

Phospholipid Transfer ProteinsApolipoproteins ACarrier ProteinsCoronary DiseaseFemaleHumansLipoprotein(a)LipoproteinsLipoproteins, HDLMaleMembrane ProteinsParticle SizePhospholipidsRisk FactorsApolipoproteins ACarrier ProteinsLipoprotein(a)LipoproteinsLipoproteins, HDLMembrane ProteinsPhospholipidsPhospholipid Transfer Proteins

Identifiers

PMID9920522
OpenAlexW1997026063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.